Three new cases of atypical thrombosis (blood clots) associated with AstraZeneca’s Covid-19 vaccine, resulted in two additional deaths in France between March 19 and 25, according to the Medicines Agency (ANSM).
Since the start of the vaccination, there have been “12 cases, including four deaths in total” of rare thromboses which have occurred in France, said the ANSM on Friday.
These are “thromboses of the large veins atypical by their location (mainly cerebral, but also digestive), which may be associated with thrombocytopenia (blood platelet deficiency) or coagulation disorders”.
The health agency, which had reported this risk a week ago, “confirms again the very rare occurrence of this thrombotic risk” in people vaccinated with the AstraZeneca vaccine.
But it nevertheless recalled that the European Medicines Agency (EMA) confirmed the “positive” benefit/risk balance of vaccination with AstraZeneca in the prevention of Covid-19.
These cases occurred within a median of nine days after vaccination, mainly in women, with no specific common history identified (nine people under 55, three patients over 55).
The ANSM recommended that people who had received this vaccine consult a doctor immediately, in the event of symptoms that persist beyond three days, such as “shortness of breath, chest pain, swelling of the legs, abdominal pain, headaches. severe headache, blurred vision, or bruising far from the injection site”.
The family of a 38-year-old woman, who died of thrombosis after receiving a first dose of the vaccine, filed a complaint against X with the Toulouse prosecutor’s office on Friday, with the aim of “obtaining an investigation,” their lawyer told AFP.
The previous report revealed nine such cases including two deaths.
A group of experts has been assembled by the European Agency to assess the mechanism of action, any underlying risk factors and any additional data to explain such cases. Their observations will be discussed during the European pharmacovigilance committee next week.